GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Institutional Ownership

Pharming Group (CHIX:PHARMA) Institutional Ownership : 5.58% (As of Jun. 28, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Pharming Group Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pharming Group's institutional ownership is 5.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pharming Group's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pharming Group's Float Percentage Of Total Shares Outstanding is 97.92%.


Pharming Group Institutional Ownership Historical Data

The historical data trend for Pharming Group's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Institutional Ownership Chart

Pharming Group Historical Data

The historical data trend for Pharming Group can be seen below:

2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31
Institutional Ownership 7.24 6.00 6.40 6.33 5.92 5.79 5.48 5.60 5.60 5.58

Pharming Group Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Pharming Group Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines